Summary of Concentra Group Holdings Parent, Inc. Q2 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $606 million, a 10% increase year-over-year from $550.8 million.

Core Revenue (excluding Pivot acquisition): $589.1 million, reflecting an 8% increase.

Occupational Health Center Patient Visits: Average of over 56,000 visits per day, up 2.6%.

Adjusted EBITDA: $140.9 million, up 22.5% from $115 million, with an adjusted EBITDA margin of 23.3%.

Adjusted Net Income: $66.7 million, adjusted EPS of $0.52, representing a 40% growth from the prior year.

Cash Flow: Operating cash flow of $135.2 million, free cash flow of $121 million, significantly up from $63.2 million year-over-year.

Debt: Total debt balance of $1.57 billion, with a net leverage ratio of just under 3x, down from 3.4x in Q1 2026.

2Strategic Updates and Business Highlights

Leadership Transition: Keith Newton will transition to Executive Chairman, while Matt DiCanio will become CEO, emphasizing continuity in leadership and strategy.

Market Share Gains: The company is seeing growth in visit volume across various industries, particularly in manufacturing and construction, attributed to effective marketing and customer retention strategies.

Employer Services Growth: Notable acceleration in Employer Services, indicating resilient hiring trends.

Onsite Health Clinics: Revenue grew 72.1% year-over-year, with a 27.9% increase excluding the Pivot acquisition, indicating strong demand and successful integration.

De Novo Expansion: One new center opened in Q2, with plans for 8-10 centers in 2026 and a pipeline for double-digit growth in 2027 and beyond.

3Forward Guidance and Outlook

Revenue Guidance: Raised to a range of $2.325 billion to $2.375 billion for 2026, up $50 million on the low end.

Adjusted EBITDA Guidance: Increased to a range of $485 million to $495 million.

Free Cash Flow Guidance: Adjusted to a range of $220 million to $240 million.

CapEx Guidance: Remains unchanged at $70 million to $80 million.

Margin Expectations: Anticipated EBITDA margins around 21%, with potential for improvement as separation costs diminish.

4Bad News, Challenges, or Points of Concern

Work Comp Visit Growth: Although visits remain strong, growth rates are expected to moderate to long-term averages of 2-3%, raising concerns about sustainability.

Market Conditions: The company is cautious about the economic environment and its impact on future growth, particularly with potential fluctuations in visit volumes.

Integration Costs: Previous integration costs from acquisitions have impacted margins, though these are expected to decline as synergies are realized.

5Notable Q&A Insights

Conservatism in Guidance: Management indicated that while they have raised guidance, they remain cautious about the second half of the year, reflecting a conservative outlook despite strong performance.

Long-term Visit Growth: Management reiterated expectations for low single-digit growth in work comp visits, with potential upside from onshoring and data center activities.

Market Share Opportunities: There is significant potential for further market penetration, especially within the Fortune 500 and small to medium-sized enterprises.

Expense Management: Continued focus on operational efficiencies and leveraging technology to enhance patient throughput and reduce costs. Overall, Concentra's Q2 2026 results reflect strong financial performance and strategic execution, though management remains vigilant about potential economic headwinds and the sustainability of current growth rates.